Stock Screener
Stock Research
Delisted Stocks
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Ironwood Pharmaceuticals Shares Outstanding 2010-2023 | IRWD

Ironwood Pharmaceuticals shares outstanding from 2010 to 2023. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  
Ironwood Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2023 155
2022 186
2021 164
2020 161
2019 156
2018 153
2017 149
2016 145
2015 142
2014 137
2013 116
2012 106
2011 100
2010 90
2009 7
Ironwood Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
2023-12-31 155
2023-09-30 187
2023-06-30 155
2023-03-31 187
2022-12-31 186
2022-09-30 184
2022-06-30 185
2022-03-31 190
2021-12-31 164
2021-09-30 165
2021-06-30 163
2021-03-31 162
2020-12-31 161
2020-09-30 160
2020-06-30 160
2020-03-31 160
2019-12-31 156
2019-09-30 157
2019-06-30 156
2019-03-31 155
2018-12-31 153
2018-09-30 153
2018-06-30 152
2018-03-31 151
2017-12-31 149
2017-09-30 150
2017-06-30 149
2017-03-31 148
2016-12-31 145
2016-09-30 145
2016-06-30 145
2016-03-31 144
2015-12-31 142
2015-09-30 142
2015-06-30 142
2015-03-31 141
2014-12-31 137
2014-09-30 139
2014-06-30 138
2014-03-31 130
2013-12-31 116
2013-09-30 121
2013-06-30 113
2013-03-31 108
2012-12-31 106
2012-09-30 114
2012-06-30 107
2012-03-31 104
2011-12-31 100
2011-09-30 100
2011-06-30 100
2011-03-31 99
2010-12-31 90
2010-09-30 98
2010-06-30 98
2010-03-31 64
2009-12-31 7
2009-09-30 7
2009-06-30 7
2009-03-31 7
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $1.265B $0.443B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $70.141B 28.83
Chugai Pharmaceutical (CHGCY) Japan $51.291B 22.93
Takeda Pharmaceutical (TAK) Japan $41.364B 6.70
Merck (MKGAF) Germany $21.368B 20.16
Astellas Pharma (ALPMY) Japan $17.264B 27.26
Sandoz Group AG (SDZNY) Switzerland $14.500B 0.00
Shionogi (SGIOY) Japan $14.029B 12.14
Neurocrine Biosciences (NBIX) United States $13.708B 56.93
United Therapeutics (UTHR) United States $11.103B 11.89
Catalent (CTLT) United States $10.098B 0.00
Cerevel Therapeutics Holdings (CERE) United States $7.639B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $6.768B 6.86
Ionis Pharmaceuticals (IONS) United States $6.098B 0.00
Revolution Medicines (RVMD) United States $5.819B 0.00
Orion OYJ (ORINY) Finland $4.940B 20.83
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $4.918B 0.00
Alpine Immune Sciences (ALPN) United States $4.236B 0.00
Madrigal Pharmaceuticals (MDGL) United States $3.868B 0.00
Crinetics Pharmaceuticals (CRNX) United States $2.943B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $2.710B 0.00
Summit Therapeutics (SMMT) United States $2.491B 0.00
Indivior (INDV) United States $2.378B 11.27
Corcept Therapeutics (CORT) United States $2.312B 23.38
Dyne Therapeutics (DYN) United States $2.042B 0.00
PTC Therapeutics (PTCT) United States $1.953B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.914B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.840B 0.00
Fusion Pharmaceuticals (FUSN) Canada $1.816B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.811B 10.73
Evotec AG (EVO) Germany $1.807B 0.00
Catalyst Pharmaceuticals (CPRX) United States $1.732B 17.90
Avadel Pharmaceuticals (AVDL) Ireland $1.614B 0.00
Taro Pharmaceutical Industries (TARO) Israel $1.597B 27.95
Ardelyx (ARDX) United States $1.468B 0.00
Soleno Therapeutics (SLNO) United States $1.248B 0.00
4D Molecular Therapeutics (FDMT) United States $1.204B 0.00
Pacira BioSciences (PCRX) United States $1.186B 11.81
Xencor (XNCR) United States $1.185B 0.00
Collegium Pharmaceutical (COLL) United States $1.172B 7.21
Cronos Group (CRON) Canada $0.955B 0.00
Cassava Sciences (SAVA) United States $0.940B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $0.896B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.858B 0.00
USANA Health Sciences (USNA) United States $0.830B 13.07
Sage Therapeutics (SAGE) United States $0.817B 0.00
Relay Therapeutics (RLAY) United States $0.815B 0.00
Enliven Therapeutics (ELVN) United States $0.785B 0.00
ARS Pharmaceuticals (SPRY) United States $0.781B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.704B 0.00
Ocular Therapeutix (OCUL) United States $0.650B 0.00
Silence Therapeutics (SLN) United Kingdom $0.647B 0.00
ProKidney (PROK) United States $0.622B 0.00
Savara (SVRA) United States $0.615B 0.00
Siga Technologies (SIGA) United States $0.614B 9.09
Calliditas Therapeutics AB (CALT) Sweden $0.579B 0.00
Lyell Immunopharma (LYEL) United States $0.561B 0.00
Verve Therapeutics (VERV) United States $0.520B 0.00
OmniAb (OABI) United States $0.519B 0.00
Altimmune (ALT) United States $0.510B 0.00
Exscientia (EXAI) United Kingdom $0.482B 0.00
Korro Bio (KRRO) United States $0.470B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.444B 0.00
KalVista Pharmaceuticals (KALV) United States $0.443B 0.00
Tourmaline Bio (TRML) United States $0.410B 0.00
Larimar Therapeutics (LRMR) United States $0.404B 0.00
Lexeo Therapeutics (LXEO) United States $0.401B 0.00
Heron Therapeutics (HRTX) United States $0.383B 0.00
Esperion Therapeutics (ESPR) United States $0.377B 0.00
Nature's Sunshine Products (NATR) United States $0.365B 20.44
Harrow (HROW) United States $0.354B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.352B 0.00
Bioventus (BVS) United States $0.322B 0.00
Fractyl Health (GUTS) United States $0.322B 0.00
Lyra Therapeutics (LYRA) United States $0.309B 0.00
Organogenesis (ORGO) United States $0.302B 57.12
Aquestive Therapeutics (AQST) United States $0.288B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.282B 0.00
Nanobiotix S.A (NBTX) France $0.279B 0.00
Akebia Therapeutics (AKBA) United States $0.278B 0.00
ESSA Pharma (EPIX) Canada $0.271B 0.00
Black Diamond Therapeutics (BDTX) United States $0.268B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.264B 0.00
Metagenomi (MGX) United States $0.253B 0.00
Xeris Biopharma Holdings (XERS) United States $0.252B 0.00
Pyxis Oncology (PYXS) United States $0.250B 0.00
Adherex Technologies (FENC) United States $0.248B 0.00
Nektar Therapeutics (NKTR) United States $0.242B 0.00
Aldeyra Therapeutics (ALDX) United States $0.234B 0.00
Conduit Pharmaceuticals (CDT) United States $0.226B 0.00
Foghorn Therapeutics (FHTX) United States $0.223B 0.00
Prelude Therapeutics (PRLD) United States $0.222B 0.00
Galectin Therapeutics (GALT) United States $0.217B 0.00
Avita Medical (RCEL) United States $0.214B 0.00
Innate Pharma SA (IPHYF) France $0.213B 0.00
Century Therapeutics (IPSC) United States $0.204B 0.00
Telomir Pharmaceuticals (TELO) United States $0.201B 0.00
Zevra Therapeutics (ZVRA) United States $0.196B 0.00
Profound Medical (PROF) Canada $0.196B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.193B 0.00
Acrivon Therapeutics (ACRV) United States $0.192B 0.00
MediWound (MDWD) Israel $0.168B 0.00
Achieve Life Sciences (ACHV) Canada $0.157B 0.00
Regulus Therapeutics (RGLS) United States $0.149B 0.00
Incannex Healthcare (IXHL) Australia $0.146B 0.00
CytoDyn (CYDY) United States $0.145B 0.00
Elite Pharmaceuticals (ELTP) United States $0.138B 12.95
Cardiol Therapeutics (CRDL) Canada $0.126B 0.00
Karyopharm Therapeutics (KPTI) United States $0.123B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.121B 2.54
Citius Pharmaceuticals (CTXR) United States $0.117B 0.00
VAXART, INC (VXRT) United States $0.116B 0.00
Relmada Therapeutics (RLMD) United States $0.112B 0.00
Inotiv (NOTV) United States $0.111B 0.00
GlycoMimetics (GLYC) United States $0.110B 0.00
OptiNose (OPTN) United States $0.102B 0.00
FibroGen (FGEN) United States $0.101B 0.00
Eliem Therapeutics (ELYM) United States $0.094B 0.00
Vivani Medical (VANI) United States $0.093B 0.00
AlloVir (ALVR) United States $0.092B 0.00
ProPhase Labs (PRPH) United States $0.089B 0.00
PMV Pharmaceuticals (PMVP) United States $0.088B 0.00
ARYA Sciences Acquisition Corp IV (ARYD) United States $0.085B 0.00
Aclaris Therapeutics (ACRS) United States $0.084B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.083B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.078B 0.00
Tempest Therapeutics (TPST) United States $0.077B 0.00
Assertio Holdings (ASRT) United States $0.075B 6.04
Journey Medical (DERM) United States $0.070B 0.00
Champions Oncology (CSBR) United States $0.069B 0.00
Carisma Therapeutics (CARM) United States $0.068B 0.00
Mural Oncology (MURA) Ireland $0.060B 0.00
SCYNEXIS (SCYX) United States $0.056B 0.83
Reneo Pharmaceuticals (RPHM) United States $0.055B 0.00
Gain Therapeutics (GANX) United States $0.050B 0.00
Jaguar Animal Health (JAGX) United States $0.047B 0.00
BioLineRx (BLRX) Israel $0.046B 0.00
Rafael Holdings (RFL) United States $0.042B 0.00
JanOne (JAN) United States $0.040B 0.00
Natural Alternatives (NAII) United States $0.039B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.039B 0.00
Protara Therapeutics (TARA) United States $0.035B 0.00
VYNE Therapeutics (VYNE) United States $0.035B 0.00
ElectroCore (ECOR) United States $0.034B 0.00
Unicycive Therapeutics (UNCY) United States $0.034B 0.00
Viracta Therapeutics (VIRX) United States $0.033B 0.00
NRx Pharmaceuticals (NRXP) United States $0.031B 0.00
CASI Pharmaceuticals (CASI) China $0.031B 0.00
Nutriband (NTRB) United States $0.029B 0.00
DURECT (DRRX) United States $0.028B 0.00
Surrozen (SRZN) United States $0.028B 0.00
Enlivex Therapeutics (ENLV) Israel $0.027B 0.00
Iterum Therapeutics (ITRM) Ireland $0.026B 0.00
Lipocine (LPCN) United States $0.024B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.024B 11.33
PolyPid (PYPD) Israel $0.023B 0.00
Oncternal Therapeutics (ONCT) United States $0.022B 0.00
TherapeuticsMD (TXMD) United States $0.022B 0.00
CERo Therapeutics Holdings (CERO) United States $0.021B 0.00
MEI Pharma (MEIP) United States $0.021B 1.04
Aptorum Group (APM) United Kingdom $0.020B 0.00
BioVie (BIVI) United States $0.020B 0.00
Talphera (TLPH) United States $0.019B 0.00
Indaptus Therapeutics (INDP) United States $0.019B 0.00
Alaunos Therapeutics (TCRT) United States $0.019B 0.00
Nuvilex (PMCB) United States $0.018B 0.00
Minerva Neurosciences (NERV) United States $0.017B 0.00
Addex Therapeutics (ADXN) Switzerland $0.016B 0.00
Dominari Holdings (DOMH) United States $0.016B 0.00
Mannatech (MTEX) United States $0.016B 0.00
Avalo Therapeutics (AVTX) United States $0.015B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.014B 0.00
Traws Pharma (TRAW) United States $0.013B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.013B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.013B 0.00
Redhill Biopharma (RDHL) Israel $0.012B 0.00
Inhibikase Therapeutics (IKT) United States $0.012B 0.00
Biomerica (BMRA) United States $0.011B 0.00
Cosmos Health (COSM) Greece $0.009B 0.00
Molecular Templates (MTEM) United States $0.009B 0.00
Universe Pharmaceuticals INC (UPC) China $0.008B 0.00
Vivos Therapeutics (VVOS) United States $0.007B 0.00
Plus Therapeutics (PSTV) United States $0.007B 0.00
Heatwurx (PCSA) United States $0.007B 0.00
Mangoceuticals (MGRX) United States $0.007B 0.00
Clever Leaves Holdings (CLVR) Canada $0.007B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.007B 0.00
Ainos (AIMD) United States $0.006B 0.00
MyMD Pharmaceuticals (MYMD) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Avenue Therapeutics (ATXI) United States $0.005B 0.00
XORTX Therapeutics (XRTX) Canada $0.005B 0.00
SHINECO (SISI) China $0.005B 0.00
Acutus Medical (AFIB) United States $0.005B 0.00
Petros Pharmaceuticals (PTPI) United States $0.004B 0.00
Finch Therapeutics (FNCH) United States $0.004B 0.00
Phio Pharmaceuticals (PHIO) United States $0.003B 0.00
TransCode Therapeutics (RNAZ) United States $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.003B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.003B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
Qualigen Therapeutics (QLGN) United States $0.002B 0.00
Bio-Path Holdings (BPTH) United States $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
InMed Pharmaceuticals (INM) Canada $0.002B 0.00
SciSparc (SPRC) Israel $0.001B 0.00
Aditxt (ADTX) United States $0.001B 0.00
China SXT Pharmaceuticals (SXTC) China $0.000B 0.00
Qilian Holding Group (QLI) China $0.000B 0.00
Context Therapeutics (CNTX) United States $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 5.24
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 44.39